- Home
- HSPO vs OPTN Comparison
HSPO vs OPTN Comparison
Compare HSPO & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSPO
- OPTN
- Stock Information
- Founded
- HSPO 2014
- OPTN 2010
- Country
- HSPO United States
- OPTN United States
- Employees
- HSPO N/A
- OPTN N/A
- Industry
- HSPO Blank Checks
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- HSPO Finance
- OPTN Health Care
- Exchange
- HSPO Nasdaq
- OPTN Nasdaq
- Market Cap
- HSPO 88.3M
- OPTN 99.7M
- IPO Year
- HSPO 2022
- OPTN 2017
- Fundamental
- Price
- HSPO $11.28
- OPTN $0.44
- Analyst Decision
- HSPO
- OPTN Strong Buy
- Analyst Count
- HSPO 0
- OPTN 3
- Target Price
- HSPO N/A
- OPTN $3.00
- AVG Volume (30 Days)
- HSPO 6.2K
- OPTN 658.7K
- Earning Date
- HSPO 01-01-0001
- OPTN 11-12-2024
- Dividend Yield
- HSPO N/A
- OPTN N/A
- EPS Growth
- HSPO N/A
- OPTN N/A
- EPS
- HSPO 0.28
- OPTN N/A
- Revenue
- HSPO N/A
- OPTN $75,672,000.00
- Revenue This Year
- HSPO N/A
- OPTN $24.44
- Revenue Next Year
- HSPO N/A
- OPTN $49.00
- P/E Ratio
- HSPO $40.04
- OPTN N/A
- Revenue Growth
- HSPO N/A
- OPTN 5.13
- 52 Week Low
- HSPO $10.63
- OPTN $0.41
- 52 Week High
- HSPO $11.30
- OPTN $2.10
- Technical
- Relative Strength Index (RSI)
- HSPO 63.55
- OPTN 24.21
- Support Level
- HSPO $11.17
- OPTN $0.66
- Resistance Level
- HSPO $11.30
- OPTN $0.81
- Average True Range (ATR)
- HSPO 0.00
- OPTN 0.06
- MACD
- HSPO 0.00
- OPTN -0.03
- Stochastic Oscillator
- HSPO 60.00
- OPTN 5.68
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.